COCRYSTAL PHARMA NEW O.N. (8CC) — Financial Flexibility Index
COCRYSTAL PHARMA NEW O.N. (8CC) has a Financial Flexibility Index of -0.51x as of December 2025. Free cash flow of €-1.74 Million (operating CF €-1.74 Million minus capex €0.00) represents -1% of total liabilities (€3.38 Million). Also explore 8CC shareholders equity momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
COCRYSTAL PHARMA NEW O.N. Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for COCRYSTAL PHARMA NEW O.N. across 5 annual periods. See COCRYSTAL PHARMA NEW O.N. (8CC) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Financial Flexibility Index for COCRYSTAL PHARMA NEW O.N. (2021–2025)
Year-by-year free cash flow to debt coverage for COCRYSTAL PHARMA NEW O.N.. For the full company profile including market capitalisation, see 8CC market cap overview.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.42x | €-8.18 Million | €-8.19 Million | €3.38 Million | ▲ +42.2% |
| 2024 | -4.19x | €-16.48 Million | €-16.48 Million | €3.93 Million | ▼ -40.4% |
| 2023 | -2.98x | €-14.55 Million | €-14.67 Million | €4.88 Million | ▲ +82.2% |
| 2022 | -16.78x | €-21.36 Million | €-21.43 Million | €1.27 Million | ▼ -144.1% |
| 2021 | -6.87x | €-12.67 Million | €-12.72 Million | €1.84 Million | — |